Results 91 to 100 of about 1,702,455 (203)

Renal transplant in a patient with idiopathic thrombocytopenic purpura refractory to steroid and intravenous immunoglobulin

Indian Journal of Transplantation, 2019
Chronic kidney disease in immune thrombocytopenia (ITP) is uncommon, and renal transplant in this setting is especially rare. We present a case of successful renal transplantation in a patient with chronic ITP refractory to steroid and intravenous ...
Shubham Agarwal, Pankaj Beniwal, Dhananjai Agarwal, Vinay Rathore   +3 more
doaj   +1 more source

Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia [PDF]

, 2018
Immune thrombocytopenia (ITP) is characterised by a transient or persistent decrease in platelets accompanied by an increased risk of bleeding, which can have a significant negative impact on patients' health-related quality of life.
Imbach, Paul, Kühne, Thomas
core  

Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohort

, 2023
Identify patient preference towards thrombopoietin-receptor agonists (TPO-RAs) and determine the clinical and social impact of immune thrombocytopenia (ITP) in Italy.
Emma Geldman (11876937), Barbara Lovrencic (16952606), Vickie McDonald (11876931), Mariasanta Napolitano (16952618), Samantha Prince (15260695), Koo Wilson (5548376), Mervyn Morgan (11876934), Owen Daykin-Pont (16952615), Daniel Eriksson (3431930), Giulio Giordano (16952609), Alessandro Lucchesi (5431655), Adrian Newland (2278714), Giuseppe Carli (16952612)   +12 more
core   +1 more source

Case Report: A case of pediatric persistent refractory ITP responsive to avatrombopag

Frontiers in Immunology
Immune thrombocytopenia (ITP) is a rare hematologic disorder characterized by low platelet counts due to an immune-mediated destruction of platelets. While corticosteroids, intravenous immunoglobulin (IVIG) are the mainstays of treatment, a subset of ...
Antonella Sau, Gianfranco Di Prinzio, Daniela Onofrillo, Anna Caterina Russo, Nicole Santoro, Mauro Di Ianni   +5 more
doaj   +1 more source

A case of chronic myelomonocytic leukemia complicated with immune thrombocytopenia

Shanghai Jiaotong Daxue xuebao. Yixue ban
Chronic myelomonocytic leukemia (CMML) complicated with immune thrombocytopenia (ITP) is rare. This article reports the clinical data of a patient with CMML complicated with ITP treated with a combination of venetoclax, ripertamab (an anti-CD20 ...
LIU Jiayu, HUANG Fang, HAO Siguo
doaj   +1 more source

Thrombopoietin-receptor agonists in haematological disorders: The Danish experience

Platelets, 2011
The objective of this study was to investigate the use of thrombopoietin-receptor agonists (TPO-ra) in patients with refractory primary immune thrombocytopenia (ITP) as well as off-label use of TPO-ra in Danish haematology departments. Hospital medical records from 32 of the 39 patients having received TPO-ra from 2009 to 1 May 2011 were available for ...
Gudbrandsdottir, S., Hasselbalch, H., Frederiksen, H.   +2 more
openaire   +3 more sources

Novel role for proteinase-activated receptor 2 (PAR2) in membrane trafficking of proteinase-activated receptor 4 (PAR4) [PDF]

, 2012
Proteinase-activated receptors 4 (PAR4) is a class A G protein-coupled receptor (GPCR) recognized through the ability of serine proteases such as thrombin and trypsin to mediate receptor activation.
Robben, Joris, Cooke, Alexandra E., Nilsson, Mary, Mundell, Stuart, Plevin, Robin, Cunningham, Margaret R., Gould, Gwyn W., McIntosh, Kathryn A., Milligan, Graeme, Pediani, John D.   +9 more
core   +2 more sources

Novel Perspectives on Thrombopoietin Receptor Agonists Applications

Hämostaseologie
Abstract Second-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag, have been proved to be significant stimulators of megakaryopoiesis and, in the last decade, they have been incorporated in the treatment options against refractory immune thrombocytopenia in children and adults that do ...
Stafylidis, Christos, Vlachopoulou, Dimitra, Syriopoulou, Stavroula, Chatzidavid, Sevastianos, Viniou, Nora-Athina   +4 more
openaire   +3 more sources

Real‐world evidence on the safety and effectiveness of thrombopoietin receptor agonists in aplastic anaemia: A descriptive study using Japanese hospital administrative data

British Journal of Haematology, Volume 209, Issue 5, Page 2374-2378, November 2026.
Kayoko Mizuno, Yutaka Shimazu, Toshiki Fukasawa, Satoru Ito, Yukihiro Nishio, Mami Shimizu, Koji Kawakami   +6 more
wiley   +1 more source

Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent

Medical Mycology, 2019
AbstractIn this study, a Food and Drug Administration (FDA)-approved drug with previously unreported antifungal activity was investigated for suitability for use as an anticryptococcal agent. First, we screened a compound library of 1018 FDA-approved drugs against Cryptococcus neoformans.
Ying-Lien Chen, Sheng-Yung Yang, Li-Hang Hsu, Hao-Tai Ko   +3 more
openaire   +3 more sources